BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 4
- Registration Number
- NCT03991494
- Locations
- 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
🇬🇧Royal Liverpool University Hospital Clinical Research Unit, Liverpool, United Kingdom
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 420
- Registration Number
- NCT03967977
- Locations
- 🇨🇳
The Second Affiliated Hospital of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 370
- Registration Number
- NCT03957590
- Locations
- 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Northern Jiangsu people's hospital, Yangzhou, Jiangsu, China
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT03941873
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT03924986
- Locations
- 🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT03905148
- Locations
- 🇦🇺
The Prince of Wales Private Hospital - Specialist Medical Randwick, Randwick, New South Wales, Australia
🇦🇺Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇺🇸University of California Los Angeles, Santa Monica, California, United States
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT03846427
- Locations
- 🇺🇸
Clinical Research Alliance, Inc, Westbury, New York, United States
🇺🇸The Charlotte Mecklenburg Hospital Authority, Charlotte, North Carolina, United States
🇦🇺The Saint George Hospital Kogarah, Kogarah, New South Wales, Australia
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 649
- Registration Number
- NCT03783442
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 997
- Registration Number
- NCT03777657
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇫🇷CHU Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷Hôpital de la Timone, Marseille, France
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 358
- Registration Number
- NCT03744468
- Locations
- 🇮🇹
Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy
🇫🇷Centre de Lutte Contre Le Cancer Francois Baclesse, Caen, France
🇮🇹Istituto Di Candiolo Irccs, Torino, Italy